Search

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers

Boehringer Ingelheim Partners with Express Scripts on their Patient Assurance Program Expansion for People with Type 2 Diabetes

Partnering

Partnering Culture

BI's long-term research and investment focus means we can work together to realize their ideas by fully committing to lasting relationships.

Boehringer Ingelheim Cares Product Donations Program

Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

Welcome to Animal Health Partnering

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists

COVID-19: Boehringer Ingelheim steps up effort with Global Support Program

Boehringer Ingelheim Fremont Employee Benefit Highlights

BI Fremont offers an excellent, competitive benefit package that takes care of you & your family. Our benefits package reflects BI’s culture & core values.

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.

Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Business Resource Groups at Boehringer Ingelheim

Business Resource Groups at Boehringer Ingelheim contribute to and help shape our company culture.

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

Boehringer Ingelheim, Sodexo and Food Rescue US Collaborate to Nourish Fairfield County’s Food Insecure in Response to the COVID-19 Crisis

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center

Boehringer Ingelheim expands free telemedicine platform to connect veterinarians and pet owners at a time of social distancing

Boehringer Ingelheim Vetmedica, Inc. to Establish North America and U.S. Headquarters in Duluth, Ga. Following Close of BI/Sanofi Asset Swap

BI increases commitments to sustainable development

At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development

Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers

Boehringer Ingelheim Partners with Express Scripts on their Patient Assurance Program Expansion for People with Type 2 Diabetes

Partnering

Partnering Culture

Boehringer Ingelheim Cares Product Donations Program

Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

Welcome to Animal Health Partnering

­­­Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists

COVID-19: Boehringer Ingelheim steps up effort with Global Support Program

Boehringer Ingelheim Fremont Employee Benefit Highlights

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Business Resource Groups at Boehringer Ingelheim

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

Boehringer Ingelheim, Sodexo and Food Rescue US Collaborate to Nourish Fairfield County’s Food Insecure in Response to the COVID-19 Crisis

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center

Boehringer Ingelheim expands free telemedicine platform to connect veterinarians and pet owners at a time of social distancing

Boehringer Ingelheim Vetmedica, Inc. to Establish North America and U.S. Headquarters in Duluth, Ga. Following Close of BI/Sanofi Asset Swap

BI increases commitments to sustainable development

Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies